Connection

AUSTIN BROWN to Antineoplastic Agents

This is a "connection" page, showing publications AUSTIN BROWN has written about Antineoplastic Agents.
Connection Strength

0.119
  1. Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2022 12; 63(12):2948-2954.
    View in: PubMed
    Score: 0.042
  2. DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors. Neuro Oncol. 2017 Oct 01; 19(10):1372-1379.
    View in: PubMed
    Score: 0.030
  3. SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. Cancer Med. 2015 Nov; 4(11):1679-86.
    View in: PubMed
    Score: 0.026
  4. The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
    View in: PubMed
    Score: 0.012
  5. Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor. J Neurooncol. 2020 Jan; 146(1):147-156.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.